Is lutetium Lu-177 dotatate FDA-approved, and what does the research show?

What is lutetium Lu-177 dotatate?

Lutetium Lu-177 dotatate is a radioactive cancer drug, and Lutathera is a brand of it ¹. Lutathera's label calls it "a radiolabeled somatostatin analog" ¹. Somatostatin is a natural hormone, an analog is a lab-made relative of one, and "radiolabeled" means a radioactive atom is attached.

The label describes three linked parts ¹. The first is a cyclic, or ring-shaped, peptide: a short chain of amino acids, the building blocks of proteins ¹. The second is a chelator, a chemical cage that grips a metal atom ¹. The third is the metal, lutetium-177, a radionuclide: an atom that gives off radiation as it decays ¹.

It is not a wellness, weight-loss or performance peptide. Lutathera is a cancer treatment, given by infusion into a vein ¹. Its label says radioactive drugs like it "should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals" ¹. A radiopharmaceutical is a drug that contains a radioactive atom.

Is lutetium Lu-177 dotatate FDA-approved?

Yes, as a prescription drug. FDA approved Lutathera on January 26, 2018, under NDA 208700 ². Its marketing status is "Prescription" as of November 9, 2026, the date of the Drugs@FDA record's data ².

Lutathera's label, revised in October 2024, gives one indication ⁶, ¹. Lutathera is "indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors" ¹.

Each term narrows who Lutathera is for. Neuroendocrine tumors are growths of hormone-releasing cells, and "gastroenteropancreatic" places them in the stomach, the intestines or the pancreas. Foregut, midgut and hindgut are the upper, middle and lower stretches of the digestive tract. The 2017 trial paper defines the midgut as "the jejunoileum and the proximal colon," the middle and lower small intestine and the first part of the colon ⁵. "Somatostatin receptor-positive" means the tumor cells carry the docking site Lutathera binds to ¹.

The label dates its latest change to the indication to April 2024 ¹. It says safety and effectiveness "have not been established in pediatric patients younger than 12 years old" with these tumors ¹.

Drugs@FDA lists two more products with the same active ingredient, each with marketing status "Prescription" as of November 9, 2026 ³, ⁴. Bexlutry, from Curium, was approved on September 14, 2026, under NDA 218525 ³. Bravnetsa, from Lantheus Medical, was approved on September 21, 2026, under ANDA 217060 ⁴. Bexlutry's label gives that use in adults ⁷. Drugs@FDA rates Bravnetsa therapeutically equivalent to Lutathera and posts no label for it ⁴.

See the FDA status of every peptide, updated weekly.

How does lutetium Lu-177 dotatate work?

Lutathera's FDA-approved label describes how the drug works ¹. The drug "binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2)" ¹. A receptor is a docking site on the surface of a cell. The trial paper says a majority of advanced, well-differentiated neuroendocrine tumors "express high levels of somatostatin receptors" ⁵.

After binding, the drug is drawn into the cell: in the label's words, "the compound is internalized" ¹. The lutetium-177 then does the damage as it decays ¹. Its "beta-minus emission," a stream of fast electrons, "induces cellular damage by formation of free radicals in somatostatin receptor-positive cells and in neighboring cells" ¹. Free radicals are reactive molecules that injure a cell from the inside.

The radiation does not reach far. The label gives its maximum penetration in tissue as 2.2 mm and its mean as 0.67 mm ¹. Lutetium-177 loses half of its radioactivity every 6.647 days, a span called its half-life ¹.

Healthy organs take up the drug as well. Within four hours it spreads to the "kidneys, tumor lesions, liver, spleen, and, in some patients, pituitary gland and thyroid" ¹. The label carries organ-by-organ radiation estimates from 20 adults in NETTER-1, the main trial ¹.

For each unit of radioactivity given, the spleen had the highest estimated dose, a mean of 0.846 gray per gigabecquerel ¹. The kidneys followed at 0.654 and the bladder wall at 0.437, against 0.052 for the whole body ¹. The gray measures radiation absorbed by tissue, and the gigabecquerel measures the radioactivity in an infusion.

The kidneys clear most of the drug, and 58 percent of it leaves in the urine within 24 hours ¹. The liver does not break it down ¹. The label says the exposure-response relationships, how the amount in the body relates to its effects, are "unknown" ¹.

What does the research show?

Lutathera is approved for a use, the top evidence tier, for the gastroenteropancreatic neuroendocrine tumors its label names ¹. Its label draws on three studies: NETTER-1, a randomized trial; ERASMUS, a large single-arm study at one site in the Netherlands; and NETTER-P, a single-arm study in pediatric patients ¹. The abstracts of the 2017 paper, NETTER-1's final report and NETTER-2 give Advanced Accelerator Applications as the funder ⁵, ⁸, ⁹. Lutathera's prescribing information is issued by Advanced Accelerator Applications USA, Inc. ⁶.

The label says efficacy "was established in NETTER-1," a randomized, open-label trial run at many centers ¹. Randomized means chance decided each patient's treatment, and open-label means patients and doctors knew which it was. The patients were adults with midgut tumors that were somatostatin receptor-positive, inoperable or spread, and growing despite octreotide ⁵, ¹. Octreotide is a somatostatin analog with no radiation attached, and the paper calls such drugs the usual first treatment ⁵.

At the primary analysis, 229 patients had been randomized ¹. Of these, 116 were assigned to Lutathera with long-acting octreotide and 113 to high-dose long-acting octreotide alone ¹. The main measure was progression-free survival, the time a patient lives without the cancer growing ¹. Reviewers who did not know each patient's treatment read the scans ¹.

By the label's table, the cancer grew or the patient died in 27 of 116 patients (23 percent) in the Lutathera arm ¹. In the comparison arm the count was 78 of 113 (69 percent) ¹. The median, the point by which half of an arm had progressed or died, was 8.5 months in the comparison arm ¹. In the Lutathera arm it had not been reached ¹.

The hazard ratio was 0.21, with a 95 percent confidence interval of 0.13 to 0.32 ¹. A hazard ratio below 1 means fewer events over time in the Lutathera arm, and the confidence interval is the range the true figure probably lies in. Tumors shrank enough to count as a response in 13 percent of the Lutathera arm and 4 percent of the comparison arm ¹.

The trial's paper, published January 12, 2017, gives somewhat different counts ⁵. At its data cutoff of July 24, 2015, it reports 23 events of progression or death in the Lutathera arm and 68 in the comparison arm ⁵. Its response rates, 18 percent against 3 percent, are among the 201 patients whose response could be assessed ⁵. It also estimates that 65.2 percent of the Lutathera arm and 10.8 percent of the comparison arm were alive without progression at month 20 ⁵.

The trial also measured overall survival, the time patients lived ¹. The label says that in the final analysis "there was no statistically significant difference in OS between the two treatment arms" ¹. By then 231 patients had been randomized, 117 and 114 in the two arms ¹, ⁸. The trial's final report, published online November 15, 2021, gives a median overall survival of 48.0 months in the Lutathera arm and 36.3 months in the comparison arm ⁸. The hazard ratio was 0.84, with a 95 percent confidence interval of 0.60 to 1.17, and the report says the survival endpoint "was not met" ⁸.

For foregut, midgut and hindgut tumors together, the label cites ERASMUS ¹. It began as expanded access, the supply of a drug outside a trial before approval, and it had no comparison arm ¹. The label says its later protocol "did not describe a specific sample size or hypothesis testing plan" ¹. Of 1,214 patients who received Lutathera, 360 had gastroenteropancreatic tumors, baseline tumor assessments and long-term follow-up ¹.

Tumors responded in 17 percent of those 360 by the investigators' own assessment, with a 95 percent confidence interval of 13 to 21 ¹. Among the 60 patients who responded, the median response lasted 35 months ¹.

The approval for ages 12 and older rests on the adult trial, with "additional safety, pharmacokinetic, and dosimetry data in pediatric patients" ¹. Those data come from NETTER-P, a single-arm study with safety data from 9 pediatric patients, 4 of whom had GEP-NETs ¹. Pharmacokinetic data track a drug's level in the body, and dosimetry estimates the radiation each organ absorbs.

Studied in people as a first treatment: NETTER-2, a randomized, open-label phase 3 trial, was published online June 5, 2024; only its abstract is cited here ⁹. Phase 3 is the large, late stage of testing. It enrolled 226 patients aged 15 or older with newly diagnosed, advanced, somatostatin receptor-positive gastroenteropancreatic tumors of higher grade 2 or grade 3 ⁹. Grade ranks how fast a tumor's cells divide, and the Ki67 index is the share of cells that stain for a marker of division. Its patients had a Ki67 index of 10 to 55 percent ⁹.

Of the 226, 151 were assigned to lutetium Lu-177 dotatate with octreotide and 75 to high-dose octreotide ⁹. By that abstract, median progression-free survival was 22.8 months in the lutetium Lu-177 dotatate arm and 8.5 months in the comparison arm ⁹. The hazard ratio was 0.276, with a 95 percent confidence interval of 0.182 to 0.418 ⁹. The abstract reports no overall-survival result, and Lutathera's label does not describe this trial ¹, ⁹.

None of the sources cited here reports a trial of lutetium Lu-177 dotatate for weight, metabolism, muscle, aging or performance ⁵, ¹, ⁸, ⁹, ⁷. Lutathera's label and the body text of the 2017 paper, without its tables and supplement, give no figures on body weight ⁵, ¹.

What are the side effects?

The main safety data in Lutathera's label come from NETTER-1: 111 patients given Lutathera with octreotide, and 112 given high-dose octreotide ¹. Nausea affected 65 percent of the Lutathera arm against 12 percent, and vomiting 53 percent against 10 percent ¹. Fatigue (38 against 26 percent), abdominal pain (26 against 19) and decreased appetite (21 against 11) were also more common ¹. The label lists no contraindications; the section reads "None" ¹.

The 2017 paper counts nausea in 65 patients (59 percent) and vomiting in 52 (47 percent) of its 111 ⁵. It says most of these cases "were attributable to amino acid infusions" given alongside the drug, and that they resolved when the infusions ended ⁵. The amino acids are there to shield the kidneys: the label says they cut the median radiation dose to the kidneys by 47 percent ¹.

Blood counts fell more often in the Lutathera arm ¹. The label calls this myelosuppression, a slowing of the bone marrow, which makes blood cells ¹. Its warning gives anemia, a low red-cell count, in 81 percent against 54 percent, and its Table 6 gives 55 percent for the comparison arm ¹. Low platelets, the cells that help blood clot, occurred in 53 percent against 17 percent ¹. Lymphopenia, a shortage of the white cells called lymphocytes, reached grade 3 or 4, the severe grades, in 44 percent against 5 percent ¹.

The label also warns of second cancers of the blood ¹. In NETTER-1 the median follow-up was 76 months ¹. Myelodysplastic syndrome, a bone marrow cancer, was reported in 2.3 percent of the Lutathera arm and in no patient in the comparison arm ¹. The abstract of the trial's final report counts two such cases among 111 patients, one of whom died, the only treatment-related death the abstract reports ⁸.

ERASMUS adds a larger group: the reviewed records of 811 patients, with a median follow-up of more than 4 years ¹. Sixteen (2.0 percent) developed myelodysplastic syndrome and 4 (0.5 percent) developed acute leukemia; the label's section 6.1 lists acute leukemia at 1 percent ¹. The median time to onset was 29 months for the syndrome and 55 months for leukemia ¹.

Eight patients (under 1 percent) developed kidney failure 3 to 36 months after treatment, and two of them needed dialysis; section 6.1 lists renal failure at 2 percent ¹. Under 1 percent had a neuroendocrine hormonal crisis, a sudden release of tumor hormones with flushing, diarrhea, bronchospasm and low blood pressure ¹. Section 6.1 lists it at 1 percent among ERASMUS's serious reactions ¹.

In NETTER-1, kidney failure was recorded in 13 percent of the Lutathera arm and 4 percent of the comparison arm ¹. The label uses it as a grouped term that includes milder falls in kidney function ¹. The 2017 paper reported no evidence of kidney toxicity at a median follow-up of 14 months ⁵. Thirteen percent of patients stopped Lutathera; five stopped for kidney-related events and four for blood toxicities ¹.

Allergic reactions, including angioedema, a swelling under the skin, have been reported since approval ¹. The label calls for patients to be watched for such reactions "in a setting where cardiopulmonary resuscitation medication and equipment are available" ¹.

The label says Lutathera "contributes to a patient's overall long-term cumulative radiation exposure," which "is associated with an increased risk for cancer" ¹. It adds that radiation "can be detected in the urine for up to 30 days" after an infusion ¹. More than 99 percent of the radioactivity leaves the body within 14 days ¹. The label directs providers to limit radiation exposure "to patients, medical personnel, and household contacts" ¹.

The label says Lutathera "can cause fetal harm when administered to a pregnant woman" ¹. It advises women who could become pregnant to use effective contraception during treatment and "for 7 months after the last dose" ¹. For men with such partners, the advice runs "for 4 months after the last dose" ¹. It advises against breastfeeding during treatment and "for 2.5 months after the last dose" ¹. It warns that the drug "may cause infertility in males and females" ¹.

Lutathera's label lists two drug interactions ¹. Somatostatin analogs "competitively bind to somatostatin receptors and may interfere with the efficacy" of the drug ¹. Glucocorticoids, a family of steroid medicines, can reduce the number of subtype 2 receptors ¹.

The risks of radiation, the label says, "are greater in pediatric patients than in adults" ¹. By its label, Lutathera has not been studied in patients with severe kidney impairment or severe liver impairment ¹.

In sport

Lutetium Lu-177 dotatate is not named on WADA's 2026 Prohibited List ¹⁰. WADA is the World Anti-Doping Agency, and section S2 of its list covers peptide hormones, growth factors, related substances and mimetics ¹⁰. Neither this drug nor somatostatin appears there or in any other section, and the list has no entry for radioactive drugs ¹⁰.

Because Lutathera is given by intravenous infusion, WADA's method rule M2.2 bears on the route ¹, ¹⁰. It prohibits "intravenous infusions and/or injections of more than a total of 100 mL per 12-hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations" ¹⁰.

What JumpstartMD offers

JumpstartMD does not prescribe lutetium Lu-177 dotatate. Our peptide library covers it so you have the facts on its FDA status and the evidence, current as of November 10, 2026.

Ready to talk?

Book FREE Consultation

Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.

Share your details and a JumpstartMD team member will reach out when we open.

Disclaimer

Compounded medications are not FDA-approved, and FDA does not review their safety, effectiveness, or quality before they are marketed. A licensed clinician decides after an evaluation whether a peptide is appropriate for you, and not every patient will qualify.